# Clinical Global Impression Severity

Protocol

AA Pharmaceutical - Subjects status

Site Number

111

Screening Number

222-001

Randomization Number

Assessment Date

27-Sep-2017

Rater

VP Tester21

Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. 1976. Rockville, MD, U.S. Department of Health, Education and Welfare | Electronic programming and presentation design copyright of MedAvante 2014

### Severity of Illness



Considering your total clinical experience with this particular population, how ill has the subject been in the past week?

| 1  | Normal, not at all ill The subject has fully recovered or has no significant residual symptoms.   |
|----|---|
| 2  | Borderline ill Some symptoms are present but these are not prominent and are not sufficient to justify a clinical diagnosis. Symptoms are not likely to cause impairment or significant distress.   |
| Х3 | Mildly ill Clear symptoms that either just fall short of diagnostic criteria or are among the least ill patients with that diagnosis. Symptoms may occasionally interfere with functioning in specific situations or may cause intermittent distress for the subject. |
| 4  | Moderately ill  Prominent symptoms that clearly meet criteria for a diagnosis. Symptoms are frequent and typically cause impairment in some areas or the subject is very distressed by the symptoms.  |
| 5  | Markedly ill Persistent, pervasive symptoms that cause problems in functioning that would typically be  |

<sup>6</sup> Severely ill Very severe and pervasive symptoms that may lead the subject to be unable to fulfill major role obligations.

#### 7 Among the most extremely ill patients

obvious to others.

The most severe level of disturbance for the diagnostic category.

# Notes

# Signature History

#### Completed and Signed by:

Name Date/Time (UTC)

222-001 27-Sep-2017 08:38

**Edited and Signed by:** 

Version Name Date/Time (UTC)

# **Audit History**

| Date (UTC)           | Attribute<br>Name | Old Value | New Value | Signed By | Change<br>Reason Type | Change<br>Reason<br>Comment |
|----------------------|-------------------|-----------|-----------|-----------|-----------------------|-----------------------------|
| 27-Sep-2017<br>08:38 | Initial version   |           |           |           |                       |                             |